In a first procedural move of its kind, NCI asked its Board of Scientific Advisors to endorse the institute’s continuing affiliation with the Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
